vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $16.5M, roughly 1.4× FrontView REIT, Inc.). FrontView REIT, Inc. runs the higher net margin — -24.9% vs -416.2%, a 391.3% gap on every dollar of revenue.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
FVR vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $23.0M |
| Net Profit | $-4.1M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | — | -428.9% |
| Net Margin | -24.9% | -416.2% |
| Revenue YoY | — | 78.8% |
| Net Profit YoY | — | 25.7% |
| EPS (diluted) | $-0.19 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | $23.0M | ||
| Q3 25 | $16.8M | $13.8M | ||
| Q2 25 | $17.6M | $14.2M | ||
| Q1 25 | $16.2M | $16.6M | ||
| Q4 24 | — | $12.9M | ||
| Q3 24 | $14.5M | $9.1M | ||
| Q2 24 | — | $7.0M | ||
| Q1 24 | — | $28.9M |
| Q4 25 | $-4.1M | $-95.8M | ||
| Q3 25 | $4.0M | $-101.3M | ||
| Q2 25 | $-2.9M | $-101.3M | ||
| Q1 25 | $-833.0K | $-114.3M | ||
| Q4 24 | — | $-128.9M | ||
| Q3 24 | $-2.4M | $-135.7M | ||
| Q2 24 | — | $-147.0M | ||
| Q1 24 | — | $-107.4M |
| Q4 25 | — | -428.9% | ||
| Q3 25 | — | -808.9% | ||
| Q2 25 | — | -772.2% | ||
| Q1 25 | — | -726.6% | ||
| Q4 24 | — | -1059.9% | ||
| Q3 24 | — | -1589.0% | ||
| Q2 24 | — | -1998.6% | ||
| Q1 24 | — | -394.0% |
| Q4 25 | -24.9% | -416.2% | ||
| Q3 25 | 23.9% | -735.2% | ||
| Q2 25 | -16.5% | -710.8% | ||
| Q1 25 | -5.1% | -687.6% | ||
| Q4 24 | — | -1001.2% | ||
| Q3 24 | -16.7% | -1489.5% | ||
| Q2 24 | — | -2112.6% | ||
| Q1 24 | — | -371.3% |
| Q4 25 | $-0.19 | $-0.81 | ||
| Q3 25 | $0.19 | $-0.92 | ||
| Q2 25 | $-0.16 | $-0.98 | ||
| Q1 25 | $-0.06 | $-1.10 | ||
| Q4 24 | — | $-1.27 | ||
| Q3 24 | — | $-1.34 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $449.9M |
| Total DebtLower is stronger | $314.3M | — |
| Stockholders' EquityBook value | $391.2M | $671.4M |
| Total Assets | $854.4M | $842.1M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | $449.9M | ||
| Q3 25 | $19.6M | $511.0M | ||
| Q2 25 | $8.4M | $459.7M | ||
| Q1 25 | $3.3M | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | — | $658.1M | ||
| Q2 24 | — | $691.1M | ||
| Q1 24 | — | $791.3M |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $391.2M | $671.4M | ||
| Q3 25 | $385.2M | $748.4M | ||
| Q2 25 | $369.9M | $715.3M | ||
| Q1 25 | $324.7M | $779.9M | ||
| Q4 24 | — | $872.0M | ||
| Q3 24 | $1.0K | $962.6M | ||
| Q2 24 | — | $971.1M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | $854.4M | $842.1M | ||
| Q3 25 | $846.8M | $925.3M | ||
| Q2 25 | $856.5M | $898.9M | ||
| Q1 25 | $860.8M | $986.2M | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $1.0K | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.3B |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $-69.3M |
| Free Cash FlowOCF − Capex | — | $-69.4M |
| FCF MarginFCF / Revenue | — | -301.6% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | $-69.3M | ||
| Q3 25 | $8.3M | $-76.9M | ||
| Q2 25 | $9.3M | $-99.6M | ||
| Q1 25 | $8.1M | $-148.9M | ||
| Q4 24 | — | $-85.2M | ||
| Q3 24 | — | $-84.8M | ||
| Q2 24 | — | $-58.2M | ||
| Q1 24 | — | $-120.7M |
| Q4 25 | — | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | — | $-86.1M | ||
| Q2 24 | — | $-59.2M | ||
| Q1 24 | — | $-123.2M |
| Q4 25 | — | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | — | -945.2% | ||
| Q2 24 | — | -850.9% | ||
| Q1 24 | — | -425.7% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 7.6% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | 14.5% | ||
| Q1 24 | — | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVR
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
